Over 700,000 cases of Zika virus infection have been reported in the Americas since 2015. (2) The emergence of Zika virus has challenged the scientific community to address a relatively uncharacterized pathogen posing a substantial threat to international public health. The two DNA vaccines assessed in this study were safe and well tolerated, and both were immunogenic. However, the greatest effects were seen with VRC5283 given in split doses via needle-free injection in the VRC 320 trial. One hundred percent (100%) of participants who received the vaccine by needle-free injection in split doses had detectable antibody responses, produced neutralizing antibodies, and had the highest T-cell responses.
“We are pleased that the PharmaJet device boosted immunogenicity in this Zika virus vaccine clinical trial and we look forward to participating in the next stage of development,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
(1) Graham BS, Enama ME, Nason MC, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One 2013; 8: e59340.
PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The Stratis device has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines intramuscularly or subcutaneously.
1-888-900-4321 Option 3